

**Prof. Dr. Peter Schirmacher**  
Director Institute of Pathology, Heidelberg



4.11.1961

Institute of Pathology  
Im Neuenheimer Feld 220  
69120 Heidelberg

06221 56 2601 (phone)  
06221 56 5251 (fax)  
[peter.schirmacher@med.uni-heidelberg.de](mailto:peter.schirmacher@med.uni-heidelberg.de)

### SCIENTIFIC VITA

1981-1987 Study of Medicine, University of Mainz  
1987 MD-Thesis (magna cum laude, Institute of Physiology, University of Mainz)  
1987-1989/  
1991-1998 Institute of Pathology, University of Mainz  
1989-1991 Postdoctoral Research Fellowship (DFG) Liver Research Center, Albert Einstein College of Medicine, New York (Prof. D.A. Shafritz)  
PhD-Study (Molecular Biology) Albert Einstein College, New York  
since 1992 Scientific Research Group leader  
1995 Board Certification Pathology  
1996 Board Certification Molecular Pathology and Habilitation  
1996-1998 Managing board DFG-SFB 519  
1998-2004 Full Professor of Pathology (C3) and Deputy Director, Institute of Pathology, University of Cologne  
2001-2004 Managing board 'Center for Molecular Medicine Cologne' (CMMC)  
since 2004 Professor of Pathology (C4) and Director, Institute of Pathology, University of Heidelberg  
since 2004 Managing board Tumorzentrum Heidelberg/Mannheim  
since 2006 Board German Association for Study of the Liver  
since 2007 Board German Society of Pathology  
since 2008 President, German Association for the Study of the Liver  
since 2008 Elected Research Area Representative (Pathology) DFG

### AWARDS:

Johannes Gutenberg Award (1988); Boehringer Ingelheim Award (1997)

### FIELDS OF INTEREST:

Molecular and morphological digestive tract carcinogenesis (especially liver and pancreas; prognostic, diagnostic, and therapeutic targets); Tumorigenic role of growth factor mediated signalling processes (IGF, WNT, HGF/MET); Chronic liver diseases and their role in initiating hepatocarcinogenesis (especially chronic viral hepatitis); molecular pathological diagnostics; tumor banking; virtual microscopy

## 10 SELECTED PUBLICATIONS (SINCE 2004; *members of the research team*)

*Straub B, Stoeffel P, Heid H, Zimbelmann R, Schirmacher P* (2008) Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis. **Hepatology** (accepted for publication)

*Schlaeger C\*, Longerich T\*, Schiller C, Bewerunge P, Mehrabi A, Toedt G, Kleeff J, Ehemann V, Eils R, Lichter P, Schirmacher P, Radlwimmer B.* (2007) Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. **Hepatology** 2007 Dec 26 (\*shared first coauthorship)

*Schaetzlein S, Kodandaramireddy NR, Ju Z, Lechel A, Stepczynska A, Lilli DR, Clark AB, Rudolph C, Kuhnelt F, Wei K, Schlegelberger B, Schirmacher P, Kunkel TA, Greenberg RA, Edlmann W, Rudolph KL.* (2007) Exonuclease-1 deletion impairs DNA damage signaling and prolongs lifespan of telomere-dysfunctional mice. **Cell** 130, 863-877.

*Singer S, Ehemann V, Brauckhoff A, Keith M, Vreden S, Schirmacher P, Breuhahn K.* (2007) Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. **Hepatology** 46, 759-768.

*Choudhury AR, Ju Z, Djojotubroto MW, Schienke A, Lechel A, Schaetzlein S, Jiang H, Stepczynska A, Wang C, Buer J, Lee HW, von Zglinicki T, Ganser A, Schirmacher P, Nakauchi H, Rudolph KL* (2007). Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. **Nat Genet** 39, 99-105

*Kern MA, Haugg AM, Koch AF, Schilling T, Breuhahn K, Walczak H, Fleischer B, Trautwein C, Michalski C, Schulze-Bergkamen H, Friess H, Stremmel W, Krammer PH, Schirmacher P, Muller M* (2006). Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. **Cancer Res** 66, 7059-7066.

*Breuhahn K, Longerich T, Schirmacher P* (2006). Dysregulation of growth factor signaling in human hepatocellular carcinoma. **Oncogene** 25, 3787-3800.

*Muller-Decker K, Furstenberger G, Annan N, Kucher D, Pohl-Arnold A, Steinbauer B, Esposito I, Chiblak S, Friess H, Schirmacher P, Berger I* (2006). Preinvasive duct-derived neoplasms in pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice. **Gastroenterology** 130, 2165-2178.

*Esposito I, Penzel R, Chaib-Harririche M, Barcena U, Bergmann F, Riedl S, Kayed H, Giese N, Kleeff J, Friess H, Schirmacher P* (2006). Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. **J Pathol** 208, 673-685.

*Breuhahn K, Vreden S, Haddad R, Beckebaum S, Stippel D, Flemming P, Nussbaum T, Caselmann WH, Haab BB, Schirmacher P* (2004). Molecular profiling of hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. **Cancer Res** 64, 6058-6064